A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder

Current Psychiatry Reports

Volumn 14, Issue 3, 2012, Pages 211-219

  Stein, Dan J ^a   Koen, Nastassja ^a   Fineberg, Naomi ^b   Fontenelle, Leonardo F ^c   Matsunaga, Hisato ^d   Osser, David ^e   Simpson, H Blair ^f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Algorithm; Anxiety disorders; Evidence based; Obsessive compulsive disorder; OCD; Pharmacotherapy; Primary care; Treatment

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CYCLOSERINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMMUNOGLOBULIN; MEMANTINE; NEUROLEPTIC AGENT; ONDANSETRON; PAROXETINE; PLACEBO; RILUZOLE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGITATION; ALGORITHM; ANXIETY; ARTICLE; BLEEDING; BRAIN DEPTH STIMULATION; CARDIOTOXICITY; CLINICAL DECISION MAKING; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; CONSENSUS DEVELOPMENT; DEPRESSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; METABOLIC SYNDROME X; NEUROPSYCHOLOGICAL TEST; OBSESSIVE COMPULSIVE DISORDER; PATIENT MONITORING; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ALGORITHMS; EVIDENCE-BASED MEDICINE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS;

EID: 84861092744     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0268-9     Document Type: Article

References (101)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602. (Pubitemid 40973434)
2. Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive compulsive disorder. Psychiatr Clin North Am. 2000;23(3):563-86. (Pubitemid 30666507)
3. Pauls DL. The genetics of obsessive compulsive disorder and Gilles de la Tourette's syndrome. Psychiatr Clin North Am. 1992;15(4):759-66. (Pubitemid 23032172)
4. Pauls DL. The genetics of obsessive compulsive disorder: a review of the evidence. Am J Med C Semin Med Genet. 2008;148C(2):133-9. (Pubitemid 351705130)
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: American Psychiatric Association; 1994.
6. Lochner C, Stein DJ. Obsessive-compulsive spectrum disorders in obsessive-compulsive disorder and other anxiety disorders. Psychopathology. 2010;43(6):389-96.
7. Koran LM. Obsessive-compulsive disorder: an update for the clinician. Focus. 2007;V(3):299-313.
8. Hollander E, Kim S, Khanna S, Pallanti S: Obsessive-compulsive disorder and obsessive-compulsive spectrum disorders: diagnostic and dimensional issues. CNS Spectrums 2007, 12(2)(suppl 3):5-13.
9. Angst J, Gamma A, Endrass J, Hantouche E, Goodwin R, Ajdacic V, Eich D, Rössler W. Obsessive-compulsive syndromes and disorders - significance of comorbidity with bipolar and anxiety syndromes. Eur Arch Psychiatry Clin Neurosci. 2005;255(1):65-71. (Pubitemid 40558108)
10. Murray CJL, Lopez AD, eds.: The global burden of disease: a comprehensive assessment of mortality and morbidity from diseases, injuries, and risk factors in 1990 and projected to 2020, Volume I. Harvard: World Health Organization; 1996.
11. Hollander E, Stein DJ, Broatch J, Himelein C, Rowland C. A pharmacoeconomic and quality of life study of obsessivecompulsive disorder. CNS Spectr. 1997;2:16-25.
12. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008;9:248-312.
13. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19:567-96. (Pubitemid 41578819)
14. Swinson RP, Antony MM, Bleau PB, et al. Clinical practice guidelines: management of anxiety disorders. Can J Psychiatry. 2006;51 Suppl 2:1-92.
15. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164 suppl 7:5-53.
16. Stein DJ, Ipser JC, Baldwin DS, Bandelow, B: Treatment of obsessive-compulsive disorder. CNS Spectr 2007, 12(2)(suppl 3):28-35.
17. Sackett DL, Rosenberg WMC, Muir Gray JA, Richards WS. Evidence-based medicine: what it is and what it isn't. BMJ. 1996;312:71-2.
18. Fawcett J, Stein DJ, Jobson KO. Textbook of treatment algorithms in psychopharmacology. Chichester: Wiley; 1999.
19. Pallanti S, Hollander E, Bienstock C, et al. Treatment nonresponse in OCD: methodological issues and operational definitions. Int Clin Psychopharmacol. 2002;5:181-91. (Pubitemid 34669829)
20. Rummel-Kluge C, Pitschel-Walz G, Kissling W. Psychoeducation in anxiety disorders: results of a survey of all psychiatric institutions in Germany, Austria and Switzerland. Psychiatry Res. 2009;169(2):180-2.
21. Hofmann SG, Smits JAJ. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebocontrolled trials. J Clin Psychiatry. 2008;69(4):621-32. (Pubitemid 351792338)
22. Eddy KT, Dutra L, Bradley R,Westen D. A multi-dimensional metaanalysis for psychotherapy and pharmacotherapy of obsessivecompulsive disorder. Clin Psychol Rev. 2004;24(8):1011-30. (Pubitemid 40247306)
23. March JS, Frances A, Carpenter D, Kahn D. Treatment of obsessivecompulsive disorder: the Expert Consensus Panel for obsessivecompulsive disorder. J Clin Psychiatry. 1997;58(suppl):1-72.
24. Franklin M, Foa E. Cognitive-behavioral treatment for obsessive compulsive disorders. In: Nathan PE, Borman JM, editors. A guide to treatments that work. New York: Oxford University Press; 1998. p. 339-57.
25. Hohagen F, Winkelmann G, Rasche-Rauschle H, et al.: Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: results of a multicentre study. Br J Psychiatry 1998, 35(suppl.):71-78. (Pubitemid 28368353)
26. Van Balkom AJ, de Haan E, van Oppen P, Spinhoven P, Hoogduin KA, van Dyck R. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis. 1998;186:492-9. (Pubitemid 28378025)
27. Cottraux J, Mollard E, Bouvard M, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol. 1990;5:17-30.
28. Foa EB, LiebowitzMR, Kozak MJ, Davies S, Campeas R, Franklin ME, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162:151-61. (Pubitemid 40095685)
29. Marks IM, Stern RS, Mawson D, Cobb J, McDonald R. Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry. 1980;136:1-25. (Pubitemid 10175757)
30. Ganasen KA, Ipser JC, Stein DJ: Augmentation of cognitive behavioral therapy with pharmacotherapy. Psychiatr Clin North Am 2010, 33(3):687-699.
31. Otto MW, Smits JAJ, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin Psychol Sci Pract. 2005;12 (1):72-86. (Pubitemid 40309355)
32. Deveney CM, McHugh RK, Tolin DF, Pollack MH, Otto MW. Combining D-cycloserine and exposure-based CBT for the anxiety disorders. Clin Neuropsychiatry. 2009;6(2):75-82.
33. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008;165:335-41. (Pubitemid 351704489)
34. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of Dcycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63(12):1118-26.
35. Eichstedt JA, Arnold SL. Childhood-onset obsessive-compulsive disorder: a tic-related subtype of OCD? Clin Psychol Rev. 2001;21:137-57.
36. Swedo SE, Leonard LH, Garvey M, et al. Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical descriptions of the first 50 cases. Am J Psychiatry. 1998;155:264-71. (Pubitemid 28074291)
37. Hollander E, Greenwald S, Neville D, Johnson J, Horning CD, Weissman MM. Uncomplicated and comorbid obsessivecompulsive disorder in an epidemiologic sample. Depress Anxiety. 1997;4:111-9. (Pubitemid 27237373)
38. Flament MF, Geller D, Irak M, Blier P: Specificities of treatment in pediatric obsessive-compulsive disorder. CNS Specr 2007, 12 (2)(suppl 3):43-58.
39. Stein D. Obsessive-compulsive disorder. Lancet. 2002;360:397-405.
40. Neziroglu F, Stevens KP, Yaryura-Tobias JA, Hoffman JH. Assessment, treatment parameters, and prognostic indicators for patients with obsessive-compulsive spectrum disorders. Cognit Behav Pract. 1999;6(4):345-50.
41. Fineberg NA, Krishnaiah RB, Moberg J, O'Doherty C. Clinical screening for obsessive-compulsive and related disorders. Israel J Psychiatry. 2008;45(3):151-60.
42. Christenson GA, Mansueto CS: Trichotillomania: descriptive characteristics and phenomenology. In Trichotillomania. Edited by Stein DJ, Christenson GA, Hollander E. Washington (DC): American Psychiatric Publishing, Inc; 1999:1-42.
43. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown obsessive compulsive scale. I: Development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006-11. (Pubitemid 19278229)
44. Rosario-Campos MC, Miguel EC, et al. The Dimensional Yale- Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions. Mol Psychiatry. 2006;11:495-504.
45. Mathis MA, Alvarenga P, Funaro G, Torresan RC, Moraes I, Torres AR, Zilberman ML, Hounie AG. Gender differences in obsessive-compulsive disorder: a literature review. Rev Bras Psiquiatr. 2011;33(4):390-9.
46. Labad J, Menchon JM, Alonso P, Segalas C, Jiminez S, Vallejo J. Female reproductive cycle and obsessive-compulsive disorder. J Clin Psychiatry. 2005;66:428-35. (Pubitemid 40593570)
47. Geller PA, Klier CM, Neugebauer R. Anxiety disorders following miscarriage. J Clin Psychiatry. 2001;62:432-8. (Pubitemid 32717876)
48. Wong IC, Besag FM, Santosh PJ, Murray ML. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf. 2004;27(13):991-1000. (Pubitemid 39487063)
49. Shear MK, Mammen O. Anxiety disorders in pregnant and postpartum women. Psychopharmacol Bull. 1995;31(4):693-703. (Pubitemid 26091737)
50. Brandes M, Soares CN, Cohen LS. Postpartum onset obsessivecompulsive disorder: diagnosis and management. Arch Womens Ment Health. 2004;7(2):99-110. (Pubitemid 38581331)
51. Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal Jr CR, Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a metaanalysis. J Perinatol. 2005;25:595-604. (Pubitemid 43118131)
52. Bloch MH, Landeros-Weisenberger A, Kelmedi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment-refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11:622-32. (Pubitemid 43989810)
53. McDougle CJ, Goodman WK, Leckman JF. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51:302-8. (Pubitemid 24127303)
54. Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ: Pharmacotherapy augmentation strategies in treatmentresistant anxiety disorders. Cochrane Database Syst Rev 2006, CD005473.
55. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M: Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2008 Jan, 23(1):CD001765.
56. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol. 1997;17(4):267-71. (Pubitemid 27312424)
57. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders, 3: tolerability, safety, and pharmacoeconomics. J Psychopharmacol. 1998;12(suppl B):S55-87. (Pubitemid 28556670)
58. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf. 1999;20:277-87. (Pubitemid 29134901)
59. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;27(1):31-40. (Pubitemid 350212624)
60. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259-66.
61. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61(11):863-7.
62. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71 (10):1259-72.
63. National Center for Biotechnology Information. U.S. National Library of Medicine. PubMed Drug & Supplements Monograph Citalopram. Available at: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a699001.html1. Accessed February 7, 2012.
64. Zohar J, Insel TR, Zohar-Kadouch RC. Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry. 1988;45:167-72. (Pubitemid 18052849)
65. Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2005;8:107-29. (Pubitemid 40388819)
66. Monteiro WO, Noshirvani HF, Marks IM, Lelliott PT. Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial. Br J Psychiatry. 1987;151:107-12. (Pubitemid 17117635)
67. Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessivecompulsive disorder. Arch Gen Psychiatry. 1996;53(7):653-4.
68. Hollander E, Kaplan A, Stahl SM. A double-blind, placebocontrolled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry. 2003;4(1):30-4.
69. Crockett BA, Churchill E, Davidson JR. A double-blind combination study of clonazepam with sertraline in obsessivecompulsive disorder. Ann Clin Psychiatry. 2004;16(3):127-32. (Pubitemid 39281271)
70. Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. 1992;12(6):420-30.
71. Denys D, van Megen HJ, van derWee N,Westenberg HG. A doubleblind switch study of paroxetine and venlafaxine in obsessivecompulsive disorder. J Clin Psychiatry. 2004;65(1):37-43.
72. Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, Birkett M, Wood AJ. A double blind placebocontrolled study of fluoxetine in patients with DSM-IIIR obsessive compulsive disorder. Eur Neuropsychopharmacol. 1993;3:143-52.
73. Tollefson G, Rampey A, Potvin J, JenikeMA, RushAJ,Dominquez RA, Koran LM, Shear MK, Goodman W, Genduso LA. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive compulsive disorder. Arch Gen Psychiatry. 1994;51:559-67. (Pubitemid 24211033)
74. Wheadon D, Bushnell W, Steiner M: A fixed dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive compulsive disorder. Poster presented at Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, Hawaii, USA. 1993.
75. Hollander E, Allen A, Steiner M,Wheadon DE, Oakes R, Burnham DB. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry. 2003;64:1113-21. (Pubitemid 37158259)
76. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:289-95.
77. Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C: Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry 2010, 15 (8):850-855.
78. Ninan PT, Koran LM, Ari K, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006;67(1):15-22. (Pubitemid 43213277)
79. Rabinowitz I, Baruch Y, Barak Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2008;23(1):49-53. (Pubitemid 350294870)
80. Pampaloni I, Sivakumaran T, Hawley CJ, Al Allaq A, Farrow J, Nelson S, Fineberg NA. High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey. J Psychopharmacol. 2010;24(10):1439-45.
81. Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR. Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(2):269-76. (Pubitemid 43357474)
82. Mundo E, Bareggi SR, Pirola R, Bellodi L, Smeraldi E. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol. 1997;17(1):4-10. (Pubitemid 27047255)
83. Nelson JC. Treatment of antidepressant nonresponders: augmentation or switch? J Clin Psychiatry. 1998;59 suppl 15:35-41. (Pubitemid 28467476)
84. Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipraine: a placebo-controlled study. Arch Gen Psychiatry. 1998;55:918-24. (Pubitemid 28465782)
85. Schruers K, Koning K, Luermans J, Haack MJ, Hriez E. Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr Scand. 2005;111:261-71. (Pubitemid 40445031)
86. Fineberg NA, Gale TM, Sivakumaran T. A review of antipsychotics in the treatment of obsessive compulsive disorder. J Psychopharmacol. 2006;21(1):97-103.
87. Dold M, Aigner M, Lanzenberger R, Kasper S. Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials. Fortschr Neurol Psychiatr. 2011;79(8):453-66 [Article in German].
88. Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol. 2007;17(2):79-93. (Pubitemid 44779187)
89. Simpson HB, Foa EB, Liebowitz MR, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008;165:621-30. (Pubitemid 351705340)
90. Simpson HB, Gorfinkle KS, Liebowitz MR. Cognitivebehavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. J Clin Psychiatry. 1999;60(9):584-90. (Pubitemid 29451554)
91. Tundo A, Salvati L, Busto G, Di Spigno D, Falcini R. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study. J Clin Psychiatry. 2007;68(10):1552-6. (Pubitemid 350073404)
92. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessivecompulsive disorder. Neurotherapeutics. 2006;3(1):69-81. (Pubitemid 43276634)
93. Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebocontrolled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72 (5):716-21.
94. Coric V, Krystal JH, Sanacora G. Glutamate agents in the treatment of mental disorders. Experimental NeuroTherapeutics. 2006;3:69-81.
95. Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30(1):34-9.
96. Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol Clin Exp. 2010;25(6):509-13.
97. Leonard HL, Swedo SE. Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS). Int J Neuropsychopharmacol. 2001;4:191-8. (Pubitemid 32587387)
98. Martino D, Defazio G, Giovannoni G. The PANDAS subgroup of tic disorders and childhood-onset obsessive-compulsive disorder. J Psychosom Res. 2009;67(6):547-57.
99. Cortese I, Chaudhry V, So Y, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294-300.
100. Nuttin BJ, Gabriels LA, Cosyns PR, et al. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery. 2003;52:1263-74. (Pubitemid 36666941)
101. Greenberg BD, Malone DA, Friehs GM, et al. Three-year outcomes in deep brain stimulation for highly resistant obsessive- compulsive disorder. Neuropsychopharmacology. 2006;31:2384-93. (Pubitemid 44607055)